{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:31:22Z","timestamp":1795033882365,"version":"4.10.2"},"reference-count":49,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Early alterations within the bone marrow microenvironment that contribute to the progression of multiple myeloma (MM) from its precursor stages could be the key to identifying novel therapeutic approaches. However, the intrinsic variability in cellular populations between patients and the differences in sample processing and analysis methods have made it difficult to identify consistent changes between data sets. Here, we used single-cell RNA sequencing of bone marrow cells from precursor stages, monoclonal gammopathy of unknown significance, smoldering MM, and newly diagnosed MM and analyzed our data in combination with a previously published data set that used a similar patient population and sample processing. Despite the vast interpatient heterogeneity, some alterations were consistently observed in both data sets. We identified changes in immune cell populations as the disease progressed, which were characterized by a substantial decrease in memory and na\u00efve CD4 T cells, and an increase in CD8+ effector T cells and T-regulatory cells. These alterations were further accompanied by an enrichment of nonclonal memory B cells and an increase in CD14 and CD16 monocytes in MM compared with its precursor stages. These results provide crucial information on the immune changes associated with the progression to clinical MM and can help to develop immune-based strategies for patient stratification and early therapeutic intervention.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007217","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T19:12:58Z","timestamp":1660763578000},"page":"5873-5883","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"first","affiliation":[{"name":"1University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Poos","sequence":"additional","affiliation":[{"name":"2University of Heidelberg, Baden-W\u00fcrttemberg, Germany"},{"name":"3German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2498-7295","authenticated-orcid":false,"given":"Michael","family":"Bauer","sequence":"additional","affiliation":[{"name":"1University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-6890","authenticated-orcid":false,"given":"Lukas","family":"John","sequence":"additional","affiliation":[{"name":"2University of Heidelberg, Baden-W\u00fcrttemberg, Germany"},{"name":"3German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Johnson","sequence":"additional","affiliation":[{"name":"1University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayu","family":"Deshpande","sequence":"additional","affiliation":[{"name":"1University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Carrillo","sequence":"additional","affiliation":[{"name":"1University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Alapat","sequence":"additional","affiliation":[{"name":"1University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"4University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[{"name":"1University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[{"name":"1University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[{"name":"1University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"1University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Davies","sequence":"additional","affiliation":[{"name":"5New York University Langone, Perlmutter Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[{"name":"2University of Heidelberg, Baden-W\u00fcrttemberg, Germany"},{"name":"3German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Morgan","sequence":"additional","affiliation":[{"name":"5New York University Langone, Perlmutter Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[{"name":"2University of Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2022111516353653600_bib1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"issue":"22","key":"2022111516353653600_bib2","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2022111516353653600_bib3","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2022111516353653600_bib4","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"25","key":"2022111516353653600_bib5","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2022111516353653600_bib6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2022111516353653600_bib7","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2022111516353653600_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ejh.12728","article-title":"Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study","volume":"97","author":"Sorrig","year":"2016","journal-title":"Eur J Haematol"},{"issue":"7","key":"2022111516353653600_bib9","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2022111516353653600_bib10","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2022111516353653600_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"2022111516353653600_bib12","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1038\/bcj.2015.49","article-title":"The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J"},{"issue":"8","key":"2022111516353653600_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0145-2126(01)00192-8","article-title":"Relationship between CD4(+)\/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16","volume":"26","author":"Koike","year":"2002","journal-title":"Leuk Res"},{"issue":"2","key":"2022111516353653600_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.leukres.2004.06.003","article-title":"High Th1\/Th2 ratio in patients with multiple myeloma","volume":"29","author":"Ogawara","year":"2005","journal-title":"Leuk Res"},{"issue":"5","key":"2022111516353653600_bib15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"12","key":"2022111516353653600_bib16","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/1078-0432.CCR-17-2627","article-title":"The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma","volume":"24","author":"Schinke","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2022111516353653600_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2022111516353653600_bib18","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J Clin Invest"},{"issue":"7","key":"2022111516353653600_bib19","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive Integration of Single-Cell Data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"issue":"9","key":"2022111516353653600_bib20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nature Methods"},{"issue":"6480","key":"2022111516353653600_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay3224","article-title":"A cell atlas of human thymic development defines T cell repertoire formation","volume":"367","author":"Park","year":"2020","journal-title":"Science"},{"issue":"4","key":"2022111516353653600_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8(+) T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"2022111516353653600_bib23","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1818488116","article-title":"Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVdelta1 and TCRVdelta2 gammadelta T lymphocytes","volume":"116","author":"Pizzolato","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022111516353653600_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fimmu.2017.00293","article-title":"Role of Distinct Natural Killer Cell Subsets in Anticancer Response","volume":"8","author":"Stabile","year":"2017","journal-title":"Front Immunol"},{"key":"2022111516353653600_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exphem.2018.09.004","article-title":"The Human Cell Atlas bone marrow single-cell interactive web portal","volume":"68","author":"Hay","year":"2018","journal-title":"Exp Hematol"},{"issue":"1","key":"2022111516353653600_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: an update","volume":"154","author":"Collin","year":"2018","journal-title":"Immunology"},{"issue":"1","key":"2022111516353653600_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13059-019-1921-y","article-title":"Distinct epigenetic features of tumor-reactive CD8+ T cells in colorectal cancer patients revealed by genome-wide DNA methylation analysis","volume":"21","author":"Yang","year":"2019","journal-title":"Genome Biol"},{"issue":"1","key":"2022111516353653600_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V98.1.23","article-title":"Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients","volume":"98","author":"Kay","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2022111516353653600_bib29","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1038\/s41467-019-12464-3","article-title":"Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease","volume":"10","author":"Szabo","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"2022111516353653600_bib30","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1038\/s41598-018-22130-1","article-title":"Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma","volume":"8","author":"Gherardin","year":"2018","journal-title":"Sci Rep"},{"issue":"7","key":"2022111516353653600_bib31","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.3324\/haematol.2017.163758","article-title":"Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition","volume":"102","author":"Favreau","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"2022111516353653600_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124698","article-title":"Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s","volume":"4","author":"Kellner","year":"2019","journal-title":"JCI Insight"},{"issue":"13","key":"2022111516353653600_bib33","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4(+)PD-1(+) Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2022111516353653600_bib34","doi-asserted-by":"crossref","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS One"},{"issue":"1-2","key":"2022111516353653600_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"2022111516353653600_bib36","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/bloodadvances.2020001434","article-title":"CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages","volume":"4","author":"Haabeth","year":"2020","journal-title":"Blood Adv"},{"key":"2022111516353653600_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cellimm.2018.02.009","article-title":"Characterization of CD4(+) T cell-mediated cytotoxicity in patients with multiple myeloma","volume":"327","author":"Zhang","year":"2018","journal-title":"Cell Immunol"},{"issue":"7","key":"2022111516353653600_bib38","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2022111516353653600_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-021-00440-4","article-title":"Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"22","key":"2022111516353653600_bib40","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1158\/1078-0432.CCR-12-0531","article-title":"Stemness of B-cell progenitors in multiple myeloma bone marrow","volume":"18","author":"Boucher","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2022111516353653600_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000203610","article-title":"Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: correlation of bone marrow granular lymphocytes to prognosis","volume":"98","author":"Sawanobori","year":"1997","journal-title":"Acta Haematol"},{"issue":"1","key":"2022111516353653600_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalhaes","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"2022111516353653600_bib43","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3109\/10428190903216804","article-title":"Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma","volume":"50","author":"Brown","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2022111516353653600_bib44","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","volume":"24","author":"Jurisic","year":"2007","journal-title":"Med Oncol"},{"issue":"1","key":"2022111516353653600_bib45","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"issue":"48","key":"2022111516353653600_bib46","doi-asserted-by":"crossref","first-page":"24242","DOI":"10.1073\/pnas.1907883116","article-title":"Single-cell transcriptomics reveals expansion of cytotoxic CD4 T cells in supercentenarians","volume":"116","author":"Hashimoto","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022111516353653600_bib47","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"issue":"9","key":"2022111516353653600_bib48","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/eji.1830270919","article-title":"T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden","volume":"27","author":"Halapi","year":"1997","journal-title":"Eur J Immunol"},{"issue":"8","key":"2022111516353653600_bib49","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/22\/5873\/1929929\/blooda_adv-2022-007217-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/22\/5873\/1929929\/blooda_adv-2022-007217-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T16:39:50Z","timestamp":1668530390000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/22\/5873\/486276\/Characterizing-the-role-of-the-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":49,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,11,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007217","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}